IntroductionCOVID-19 pandemic represents a major worldwide challenge, with a great impact on health systems and economic mechanisms. SARS-CoV-2, the pathogen agent that generates COVID-19, creates a wide variety of organ dysfunctions, from acute respiratory distress syndrome (ARDS) to acute myocardial infarction or pulmonary embolism. Mechanical circulatory support devices such as Extracorporeal Membrane Circulatory Oxygenation (ECMO) have shown their efficacy in maintaining organs perfusion in respiratory and cardiac impairments. With this review, we aimed to assess the impact of ECMO use in COVID-19 patients with ARDS.Material and methodsWe performed a systematic review to find the studies using ECMO in COVID-19. Comorbidities, side effects, and survival rate to discharge were analysed. The literature search was done using PubMed/MEDLINE, Web of Science, Embase (Elsevier), the Cochrane Central Register of Controlled Trials (Wiley) and clinicaltrials.gov databases (inception (December 2019) to October 16, 2021), by 2 authors.ResultsWe included 33 studies from 10 countries with a total of 4.760 patients receiving ECMO for COVID-19. Survival rate varied from 9% to 90,6% at discharge. The most serious adverse events were acute kidney injury (up to 87%), major bleeding (up to 92,1%), strokes or cerebral hemorrhage (up to 34%). Other complications such as pulmonary embolism, peripheral bleeding, or sepsis had a major impact on survival rates.ConclusionsECMO in COVID-19 patients may be a useful rescue therapy instrument, but due to the great variability of studies and still unknown mechanisms and effects of the SARS-CoV-2, further studies are need to be done.